Phase III Trial Success for Fenebrutinib Offers First Effective Oral Treatment for Primary Progressive MS

The central challenge in treating multiple sclerosis has long been a geographical one. While modern therapies can effectively calm the immune system in the bloodstream, they struggle to cross the blood-brain barrier to stop the "smoldering" inflammation deep within the central nervous system. This is particularly devastating for primary progressive multiple sclerosis (PPMS), a form of the disease characterized by a steady, relentless accumulation of disability rather than distinct relapses. For over a decade, only a single intravenous therapy has been approved to slow this decline, leaving many patients with limited options as their physical independence slowly wanes.[1][3]

That landscape is now shifting. Late-breaking Phase III clinical trial data presented this year reveals that an experimental oral medication called fenebrutinib has successfully met its primary endpoints in treating both primary progressive and relapsing forms of MS. Developed by Genentech and Roche, the drug represents the first time a new mechanism of action has proven effective against PPMS in a late-stage trial since the approval of ocrelizumab (Ocrevus). The findings offer the most concrete evidence to date that targeting inflammation directly inside the brain can alter the trajectory of the disease.[1][3]

To understand why this matters, it helps to look at how fenebrutinib works. It belongs to a class of drugs known as Bruton's tyrosine kinase (BTK) inhibitors. BTK is an enzyme that acts as a crucial signaling node for B cells and microglia—immune cells that drive the inflammatory attacks on the myelin sheath protecting nerve fibers. While older therapies broadly deplete B cells in the periphery, BTK inhibitors are designed to modulate their activity without wiping them out entirely, potentially preserving more of the body's baseline immune function.[1][3]

Unlike older, larger biologic drugs that remain largely in the bloodstream, fenebrutinib is a small molecule designed to be highly central nervous system penetrant. It crosses the blood-brain barrier to directly inhibit the microglia residing within the brain and spinal cord. By quieting these specific cells, the drug aims to halt the chronic, localized damage that drives long-term disability in progressive MS—the smoldering inflammation that peripheral treatments cannot reach.[1][4]

The strongest evidence for this approach comes from the FENtrepid study, a massive Phase III trial involving 985 adults with PPMS. The trial was designed as a head-to-head non-inferiority comparison against ocrelizumab, the current standard of care. Participants received either daily oral fenebrutinib or intravenous ocrelizumab for at least 120 weeks. Progress was measured through a composite endpoint that incorporated the expanded disability status scale, walking speed, and upper limb function, offering greater sensitivity than traditional measures.[1][4][5]

The data showed that fenebrutinib met its primary endpoint of non-inferiority to ocrelizumab in reducing 12-week confirmed disability progression. In fact, the oral drug numerically outperformed the infusion, reducing the overall risk of disability progression by 12% compared to the active control. The treatment curves between the two drugs began to separate as early as 24 weeks into the trial, suggesting that the brain-penetrant mechanism may act rapidly on the inflammation driving progressive disability.[1][4][5]

The clinical benefits were particularly pronounced in specific functional areas. Researchers highlighted a 26% reduced risk of worsening in upper limb function, measured by the nine-hole peg test, compared to ocrelizumab. This metric is critical for patients with PPMS, as preserving hand and arm dexterity directly correlates with maintaining daily independence, the ability to work, and overall quality of life.[1][5]

Beyond progressive MS, fenebrutinib was also evaluated in two identically designed Phase III trials for relapsing multiple sclerosis (RMS), dubbed FENhance 1 and FENhance 2. These trials compared the BTK inhibitor against teriflunomide (Aubagio), a widely used oral standard-of-care medication, in nearly 1,500 patients. The goal was to see if the same mechanism that slows progression could also prevent the acute inflammatory attacks characteristic of relapsing disease.[2][6]

The results in the relapsing populations were definitive. In FENhance 1, fenebrutinib reduced the annualized relapse rate by 51% compared to teriflunomide over 96 weeks. FENhance 2 demonstrated an even steeper 59% reduction. According to researchers, this equates to an estimated rate of approximately one relapse every 17 years for patients on fenebrutinib, representing a profound suppression of disease activity.[2][6]

Secondary endpoints in the RMS trials reinforced the primary findings. Both studies showed statistically significant reductions in the formation of new brain lesions on MRI scans. The drug also demonstrated favorable trends in reducing disability progression in the relapsing population, mirroring the effects seen in the PPMS cohort and validating the dual-action approach of targeting both peripheral and central inflammation.[2][6]

While the efficacy data is robust, the safety profile of BTK inhibitors remains an area of active scrutiny. Fenebrutinib is a non-covalent, reversible inhibitor, which researchers believe may limit off-target effects compared to older drugs in the class that form permanent bonds. In the FENtrepid trial, serious adverse events were comparable between fenebrutinib (19.1%) and ocrelizumab (18.9%), with common issues including nausea and respiratory tract infections.[1][4]

However, the data does show areas of concern that regulators will weigh heavily. Transient liver enzyme elevations were more frequent in the fenebrutinib group (13.3%) compared to the ocrelizumab group (2.9%). While no cases of severe drug-induced liver injury were reported in the FENtrepid study, liver toxicity has been a class-wide issue that has stalled or halted the development of other BTK inhibitors for MS, making this a critical safety metric.[1]

The trial also recorded a numerically higher rate of fatal cases in the fenebrutinib arm (1.4%) versus the ocrelizumab arm (0.2%). Investigators assessed all of these fatalities as unrelated to the study treatment, noting no pattern in timing or cause. Epidemiological studies show that fatality rates are inherently higher in people living with MS, but regulatory agencies will undoubtedly scrutinize this imbalance closely during the approval process.[1][3]

The totality of the data from the FENtrepid and FENhance programs provides the most comprehensive evidence to date that targeting BTK within the central nervous system can alter the trajectory of multiple sclerosis. Roche has announced plans to submit the complete data package to global regulatory authorities in mid-2026, setting the stage for a potential paradigm shift in MS care.[1][5]

If approved, fenebrutinib would become the first high-efficacy oral treatment available for both relapsing and primary progressive forms of the disease. For the MS community, the results offer a tangible validation of a new biological target—and the prospect of a daily pill that can finally reach the inflammation driving their most relentless symptoms.[1][5]